FY2025 EPS Estimate for ProQR Therapeutics Lifted by Analyst

ProQR Therapeutics (NASDAQ:PRQR) – Stock analysts at Chardan Capital lifted their FY2025 earnings per share (EPS) estimates for shares of ProQR Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst K. Nakae now anticipates that the biopharmaceutical company will earn ($0.33) per share for the year, up from their prior estimate of ($0.34). Chardan Capital currently has a “Buy” rating and a $4.00 target price on the stock. The consensus estimate for ProQR Therapeutics’ current full-year earnings is ($0.31) per share.

Other analysts also recently issued research reports about the stock. Citigroup upgraded shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective for the company in a research report on Monday, March 10th. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 target price on shares of ProQR Therapeutics in a report on Thursday, December 12th. StockNews.com cut shares of ProQR Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, November 28th. Oppenheimer began coverage on shares of ProQR Therapeutics in a research note on Friday, January 10th. They issued an “outperform” rating and a $15.00 price objective on the stock. Finally, HC Wainwright increased their target price on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research note on Friday, March 14th. One investment analyst has rated the stock with a sell rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $9.50.

ProQR Therapeutics Stock Down 5.9 %

Shares of PRQR opened at $1.43 on Thursday. The company has a market capitalization of $150.45 million, a price-to-earnings ratio of -4.47 and a beta of 0.24. ProQR Therapeutics has a 52-week low of $1.43 and a 52-week high of $4.62. The stock has a 50 day moving average price of $2.10 and a 200 day moving average price of $2.59.

Institutional Trading of ProQR Therapeutics

Several hedge funds have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in shares of ProQR Therapeutics during the fourth quarter worth about $30,000. Invesco Ltd. acquired a new position in ProQR Therapeutics during the 4th quarter worth approximately $32,000. Alpine Global Management LLC purchased a new position in shares of ProQR Therapeutics during the 4th quarter worth approximately $39,000. Two Sigma Securities LLC acquired a new stake in shares of ProQR Therapeutics in the 4th quarter valued at approximately $40,000. Finally, ADAR1 Capital Management LLC purchased a new stake in shares of ProQR Therapeutics in the fourth quarter valued at approximately $54,000. Institutional investors and hedge funds own 32.65% of the company’s stock.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).